Skip to main content

Table 2 Adverse events (AE) in children receiving oral oseltamivir

From: Pharmacokinetics of oseltamivir in infants under the age of 1 year

Patient number

Age

months (m) and days (d)

Comorbidities

Clinical AE

Laboratory changes

1

6 m, 23 d

Tetralogy of Fallot

D1

Dry-retching

Day 1 bloods: raised creatinine (48 mmol/L) and AST (66 mmol/L)

Attributed to cardiac condition

Normalised after frusemide dose during course of oseltamivir

2

5 m, 13 d

Albright’s osteodystrophe

Hypothyroidism

Hypoparathyroidism

GORD

Severe OSA due to epiglottis dystrophy

Nil

Nil

3

11 m, 15 d

Streptococcus pneumoniae bacteraemia, pneumonia, meningitis

Parainfluenza 3/rhinovirus/enterovirus co-infection

Developed HUS

Nil

Baseline bloods normal

D2 of oseltamivir: rising creatinine, urea, AST/ALT/GGT

All parameters normalised 10 days after first dose

Laboratory abnormalities attributed to HUS

4

3 m, 13 d

Exomphthalmos

Nil

Nil

  1. GORD gastro-oesophageal reflux disease, OSA obstructive sleep apnoea, HUS haemolytic uraemic syndrome